Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers

Current Hypertension Reports

Volumn 4, Issue 5, 2002, Pages 333-335

  Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; LOSARTAN; RECEPTORS, ANGIOTENSIN; RISK FACTORS;

EID: 0036781302     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0059-5     Document Type: Note

References (11)

1. Weir MR: Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Am Fam Physician 1996, 53: 589-594.
2. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145-153.
3. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: a randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355: 1582-1587.
4. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345: 1667-1675.
5. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345: 861-869.
6. Parving HH, Lehnert H, Brochner J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345: 870-878.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
8. Lindholm LH, Ibsen H, Dahlor B, et al., for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359: 1004-1010.
9. Azizi M, Guyene TT, Chatellier G, et al.: Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997, 29: 634-640.
10. Russo D, Pisani A, Balletta MM, et al.: Additive antiproteinuric effect of a converting-enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999, 33: 851-856.
11. Weir MR, Weber MA, Neutel JM, et al., for the ACTION study Investigators. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy; a clinical experience trial. Am J Hypertens 2001, 14: 567-572.